CVS Health Earnings Call: Cash, Growth And Cost Risks
CVS Health Corp ((CVS)) has held its Q4 earnings call. Read on for the main highlights of the call.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CVS Health Corp’s latest earnings call struck a cautiously optimistic tone, as management showcased strong 2025 execution, robust cash generation, and improving profitability in core businesses like Aetna and pharmacy. At the same time, they acknowledged real headwinds from Medicare Advantage rate pressure, elevated medical costs, and regulatory uncertainty that could weigh on margins beyond 2026.
Strong 2025 Financial Outperformance
CVS closed 2025 with revenue above $400 billion and adjusted EPS of $6.75, roughly 15% ahead of initial expectations, underscoring powerful operating leverage. Operating cash flow hit $10.6 billion, well above early plans and signaling that the business is throwing off ample cash to fund investment and de‑leveraging.
Solid Fourth Quarter Sets the Tone
Fourth quarter revenue surpassed $105 billion, up more than 8% year over year, with adjusted operating income near $2.6 billion and EPS of $1.09. Cash generation was also strong in the quarter, with about $3.4 billion in operating cash flow, reinforcing the full‑year cash performance.
Aetna’s Profitability Recovery Gains Traction
Aetna delivered a more than $2.6 billion improvement in adjusted operating income in 2025, marking a sharp year‑over‑year turnaround. Management emphasized stronger leadership, a reinforced culture, sustained leading Stars ratings, and recognition via Press Ganey’s Health Plan of the Year as proof of progress.
Retail Pharmacy & Consumer Wellness Momentum
Pharmacy & Consumer Wellness posted nearly $38 billion of Q4 revenue, up 12% year over year, with same‑store revenue up 16% and pharmacy sales up 19%. Same‑store prescription volume climbed almost 10%, driving Q4 segment adjusted operating income above $1.9 billion and full‑year profit above $6 billion, both growing mid‑single digits.
Health Services and Oak Street Health Drive Growth
Health Services produced more than $51 billion of Q4 revenue, up 9% versus last year, and roughly $1.9 billion in adjusted operating income, also up about 9%. Within that, Health Care Delivery revenue excluding CVS Accountable Care grew about 21%, fueled by patient growth at Oak Street Health.
Retail & PBM Strategic Shifts Take Hold
CVS Pharmacy completed its transition to cost‑based reimbursement, which management believes stabilizes the business with at least flat annual earnings expected from 2026 onward. Caremark’s TrueCost model continues to evolve, and leadership argued that recent PBM legislation should be manageable and could actually hasten adoption of this more transparent structure.
Massive Savings Delivered to Clients and Members
Across Aetna and Caremark, CVS highlighted more than $280 billion of annual savings for customers, including $235 billion from Aetna network negotiations and roughly $45 billion from Caremark deals. Its HUMIRA biosimilar strategy achieved approximately 96% adoption and zero out‑of‑pocket costs for more than 80% of members, yielding over $1.5 billion in savings.
Balance Sheet Strengthens on Cash Generation
Year‑end cash at the parent and unrestricted subsidiaries reached about $2.8 billion, reflecting improved liquidity. The leverage ratio improved to around 4x, a meaningful step down from the prior year, and management expects further de‑leveraging as earnings and cash flow continue to build.
Signify Health Expands In‑Home Clinical Reach
CVS underscored the strategic value of Signify, whose clinicians conduct in‑home, provider‑led evaluations for more than 3.5 million consumers annually. Those visits drove over 500,000 care connections, including nearly 100,000 urgent escalations, helping close gaps in care and deepening clinical engagement.
Medicare Advantage Faces 2027 Rate Pressure
Management labeled the preliminary 2027 Medicare Advantage advanced rate notice as disappointing, arguing proposed rates do not keep pace with actual medical trends. They warned of potential margin pressure in MA despite an ongoing commitment to restore margins, and said advocacy efforts with regulators are underway.
Health Care Benefits Q4 Loss and Membership Erosion
In Health Care Benefits, CVS reported a Q4 adjusted operating loss of $676 million, slightly worse than last year, highlighting ongoing pressure in that segment. Medical membership ended at about 26.6 million, down roughly 500,000 year over year and modestly sequentially, largely tied to Individual Exchange and Government program declines.
Risk Adjustment, Flu Activity and MBR Headwinds
Results were hurt by a deterioration in risk adjustment performance in the Individual Exchange business and a late‑quarter provision for increased flu activity. Together with Medicaid pass‑through effects, these items added roughly 20 basis points to the 2025 medical benefit ratio, lifting it to 91.2% and underscoring fragile margins.
Seasonality Shifts From the Inflation Reduction Act
Changes in Medicare Part D seasonality stemming from the Inflation Reduction Act weighed on Q4 Health Care Benefits results and medical benefit ratio dynamics. Management noted that the new timing of costs and subsidies is complicating quarterly patterns and contributed to the segment’s reported weakness.
PBM Regulation Adds Uncertainty But Also Opportunity
CVS acknowledged ongoing regulatory scrutiny of PBM operations and evolving legislation, including guaranteed rebate models and reimbursement pressure that will be headwinds in 2026. However, the team believes the rules are manageable and may accelerate migration to its TrueCost model, which could deepen relationships with cost‑conscious clients.
Cash Flow Timing and 2026 Outlook
Some payments that were originally expected in early 2026 instead arrived late in 2025, boosting reported 2025 cash flow but reducing 2026’s starting point. As a result, CVS now guides to at least $9 billion of operating cash flow in 2026, slightly below prior expectations, and emphasized this shift reflects timing, not weakening fundamentals.
Persistent Elevated Medical Cost Trends
Management cautioned that medical cost trends remain elevated across products and will pressure profitability. They project about an 850 basis point increase in the medical benefit ratio from Q1 to Q4 of 2026, slightly steeper than previously expected, implying a tough cost environment even as other parts of the business perform well.
Guidance and Forward‑Looking Outlook
CVS reaffirmed its 2026 targets of at least $400 billion in revenue, adjusted EPS of $7.00 to $7.20, and operating cash flow of at least $9 billion, with about 55% of earnings expected in the first half. Management also highlighted that cumulative cash flow expectations for 2025–2026 have risen by more than $1.5 billion, supported by Aetna’s earnings rebound and strong Pharmacy & Consumer Wellness performance.
CVS’s earnings call painted a picture of a diversified health‑care giant regaining its footing, with strong 2025 results, improving balance sheet metrics, and clear momentum in pharmacy, services, and Aetna. Investors will now watch whether management can sustain this trajectory while navigating Medicare Advantage rate cuts, regulatory shifts, and stubbornly high medical costs.
Disclaimer & DisclosureReport an Issue
